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Abstract
Background: Low skeletal muscle mass is associated with 
increased postoperative morbidity and worse survival fol-
lowing resection for perihilar cholangiocarcinoma (PHC). We 
investigated the predictive value of skeletal muscle mass 
and density for overall survival (OS) of all patients with sus-
pected PHC, regardless of treatment. Methods: Baseline 
characteristics and parameters regarding disease and treat-
ment were collected from all patients with PHC from 2002 to 
2014. Skeletal muscle mass and density were measured at 
the level of the third lumbar vertebra on CT. The association 
between skeletal muscle mass and density with OS was in-
vestigated using the Kaplan-Meier method and Cox survival. 
Results: Median OS in 233 included patients did not differ 
between those with and without low skeletal muscle mass 
(p = 0.203), whereas a significantly different median OS 
(months) was observed between patients with low (HR 7.0, 
95% CI 4.7–9.3) and high (HR 12.1, 95% CI 8.1–16.1) skeletal 
muscle density (p = 0.004). Low skeletal muscle density was 
independently associated with decreased OS (HR 1.78, 95% 
CI 1.03–3.07, p = 0.040) within the first 6 months but not after 
6 months (HR 0.68, 95% CI 0.44–1.07, p = 0.093), after adjust-
ing for age, tumour size and suspected peritoneal or other 
distant metastases on imaging. Conclusion: A time-depen-
dent effect of skeletal muscle density on OS was found in 
patients with PHC, regardless of subsequent treatment. Low 
skeletal muscle density may identify patients at risk for early 
death. © 2018 The Author(s) 
Published by S. Karger AG, Basel
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Introduction
The prognosis of patients with perihilar cholangiocar-
cinoma (PHC) is poor. After curative-intent resection, 
the median survival is 19–39 months with a 5-year sur-
vival rate of 10–40% [1–3]. However, only about 1 in 4 
patients with suspected PHC undergoes surgical resec-
tion. The majority of patients receive palliative treatment 
or best supportive care and have a median survival of only 
6 months [4–7].
Multiple staging systems are available to predict prog-
nosis in patients with (suspected) PHC [4, 8–10]. How-
ever, the majority of staging systems, such as the fre-
quently used American Joint Committee on Cancer 
(AJCC) staging system, are applicable only to a minority 
of patients who undergo resection [8]. Prognostic factors 
and models for all PHC patients regardless of treatment 
are rare [10].
Recently, low skeletal muscle mass (i.e., sarcopenia), as 
part of the cancer cachexia syndrome [11, 12], has been 
introduced as a biomarker to predict treatment complica-
tions and worsened survival in gastrointestinal and hepa-
topancreatobiliary cancer patients [13, 14]. It may detect 
malnutrition that is not visible otherwise [15]. Three stud-
ies found that preoperative low skeletal muscle mass was 
also associated with worse outcome in patients undergo-
ing surgical resection of extrahepatic biliary cancer [16] 
and PHC [17, 18]. Moreover, low skeletal muscle density, 
as a measure of intramuscular adipose tissue infiltration, 
has been identified as a prognostic parameter that might 
be even stronger than skeletal muscle mass [19]. However, 
the association between sarcopenia and outcome in all 
PHC patients, regardless of treatment, and the prognostic 
value of skeletal muscle density remain unknown.
Methods
Patients and Data Collection
All patients aged 18 years and older with suspected PHC who 
presented between 2002 and 2014 were identified. Demographics 
and clinical, drainage, laboratory, and treatment parameters were 
collected from medical records. Body mass index (BMI) was catego-
rized according to the World Health Organization classification 
[20]. PHC was defined as a mass at or near the biliary confluence, 
arising between the origin of the cystic duct and the segmental bile 
ducts [21]. In the absence of histopathological evidence, the diag-
nosis of suspected PHC was based on the opinion of the multidisci-
plinary hepatopancreatobiliary team based on clinical, radiological, 
endoscopic, and laboratory observations. Patients were excluded if 
benign disease was considered more likely during follow-up. Pa-
tients who visited our centre for drainage only once, or who already 
underwent treatment in the referral centre, were also excluded.
Radiological examinations (contrast-enhanced CT and/or MRI 
with or without cholangiopancreatography [MRCP]) were re-as-
sessed by an experienced abdominal radiologist. Parameters as-
sessed on imaging were tumour visibility, tumour size, Bismuth-
Corlette classification [22], vascular involvement [9], lobar atrophy, 
lymph node status, and the presence of distant metastases. Based on 
these findings, the AJCC stage (7th edition) was assessed [21]. Stag-
es I and II were analysed together for the clinical AJCC stage, be-
cause T1 (stage I) and T2 (stage II) cannot be distinguished on im-
aging alone. Vascular involvement was defined as tumour contact 
of at least 180 degrees around the portal vein and/or hepatic artery 
and its side branches. Involvement of lymph nodes along the cystic 
duct, common bile duct, hepatic artery and portal vein was classi-
fied as N1 and lymph node involvement around the aorta, caval 
vein, superior mesenteric artery and celiac artery as N2 [21].
The municipal records database was checked for survival status 
on May 9, 2016. A waiver was granted for this study from the In-
stitutional Review Board.
Diagnostic Work-Up and Treatment Algorithm
The diagnostic work-up included, but was not limited to, imag-
ing with contrast-enhanced CT, and MRI with or without MRCP. 
Typically, patients were only considered for exploratory laparoto-
my in the absence of metastatic disease and with involvement of 
<180 degrees of the hepatic artery. A resection was performed only 
when a complete resection (R0) was anticipated with an adequate 
functional liver remnant. Patients with metastatic or locally ad-
vanced disease were offered palliative chemotherapy. All other pa-
tients received best supportive care and palliative drainage.
Skeletal Muscle Mass and Density
Skeletal muscle mass was measured on abdominal CT, using an 
in-house developed software package as previously described [23, 
24]. In short, the cross-sectional skeletal muscle area (CSMA, in 
cm2) was measured at the level of the third lumbar vertebra (L3) 
using a Hounsfield unit range of –30 to 150. The CSMA was ad-
justed for patients’ height squared, as is conventional for body 
composition measurements, resulting in the skeletal muscle index 
(cm2/m2) that is strongly correlated with total body skeletal muscle 
mass [25, 26]. Low skeletal muscle index was defined according to 
previously defined cut-off values in patients with PHC undergoing 
surgery [17]. The mean Hounsfield unit value of the CSMA, as a 
measure of skeletal muscle density that is closely related to muscle 
function [19, 27], was also recorded. Low skeletal muscle density 
was defined as a value below the sex-specific median [28]. 
The first abdominal CT during the diagnostic work-up of PHC 
was used. If no CT was available or not all skeletal muscles at the 
level of L3 were depicted on, patients were excluded.
Statistical Analyses
Continuous data are reported as median with interquartile 
range or mean ± SD, depending on the normality of the distribu-
tion. Normality of the distribution was tested using the Shapiro-
Wilk test. Categorical variables are reported as counts with per-
centages. Fischer’s exact or chi-square tests were used for the com-
parison of proportions, while continuous parameters were 
compared using Students t tests. 
Overall survival (OS) was measured from the date of first pre-
sentation in the tertiary referral centre. Survival estimates were 
compared using the Kaplan-Meier method and the log-rank test. 
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Logistic regression analysis was used to compare the 3-month, 
6-month, 1-, 3-, and 5-year survival rates. The association between 
skeletal muscle mass and density and survival was investigated us-
ing a multivariable Cox proportional hazard regression model, ad-
justing for known risk factors [10] and additional factors that were 
associated with impaired survival in univariable analysis. Hazard 
ratios (HRs) with 95% CI were reported. Due to the large number 
of missing values, CA19-9 was not included in the final model. A 
subgroup analysis was performed only in unresectable patients. 
The effect of skeletal muscle density on the hazard was allowed to 
vary before and after 6 months of follow-up. Therefore, an interac-
tion term between time and skeletal muscle density was included 
in the Cox regression model [29]. Finally, a sensitivity analysis was 
performed using the cut-off values defined by Martin et al. [19]. 
Two-tailed p values below 0.05 were considered statistically sig-
nificant. All statistical analyses were performed using SPSS for 
Windows version 22 (IBM Corp., Armonk, NY, USA).
Results
Patient and Tumour Characteristics
In total, 285 patients with suspected PHC in our cen-
tre were identified. Of these 285 patients, 233 (81.8%) 
had a contrast-enhanced abdominal CT and formed the 
study cohort. Body height was missing for 23 (9.9%) pa-
tients. Consequently, these patients were excluded from 
analyses requiring body height (i.e., skeletal muscle 
mass), but included in analyses using skeletal muscle 
density. Due to missing body height and/or weight, BMI 
was unknown for 50 (21.5%) patients. The median time 
between the first available contrast-enhanced CT per-
formed for the suspicion on PHC and the first presenta-
tion in the tertiary referral centre was 11 (3–25) days 
(Table 1).
Treatment Characteristics
Forty-one (17.6%) patients underwent surgical resec-
tion including 2 liver transplantations, and 72 (30.9%) 
patients underwent a laparotomy without resection. In 
these 72 patients, the intraoperative finding of metastases 
and locally advanced disease were the most common rea-
sons for renouncing resection. The remaining 120 (51.5%) 
patients were considered unresectable at initial presenta-
tion, of whom 13 (11.3%) received palliative chemother-
apy.
Low Skeletal Muscle Mass
In total, 103 of the 210 (49.0%) of patients were 
considered to have low skeletal muscle mass (Table 1). 
Patients with low skeletal muscle mass were signifi-
cantly older compared with patients with high skeletal 
muscle mass (69 vs. 64 years, p = 0.040) and had sig-
nificantly higher C-reactive protein and CA19-9 levels. 
Median BMI was significantly lower in patients with 
low versus high skeletal muscle mass (23.7 vs. 25.7, p < 
0.001). The rate of metastatic disease at initial presen-
tation was significantly higher in patients with low 
skeletal muscle mass (15.5 vs. 4.7%, p  = 0.009) and 
non-significant differences were observed in treatment 
groups.
Low Skeletal Muscle Density
Low skeletal muscle density was observed in 131 
(56.2%) patients (Table 1). BMI was significantly higher 
in patients with low skeletal muscle density compared 
with high skeletal muscle density (25.2 vs. 24.4, p = 0.032). 
Furthermore, patients with low skeletal muscle density 
had a higher CRP level (17 vs. 9, p = 0.023), more often 
had unresectable disease (87.0 vs. 78.0%, p < 0.001) and 
were less frequently treated with chemotherapy (8.8 vs. 
21.7%, p = 0.007).
Overall Survival
In total, 221 (94.8%) patients died during the study pe-
riod. Median follow-up of the included patients who were 
alive at last follow-up was 25.3 (18.3–85.5) months. The 
3-month, 6-month, 1-, 3-, and 5-year OS rates in the en-
tire cohort were 79.0, 60.9, 42.1, 7.7, and 3.0% respective-
ly. Median OS for the entire cohort was 9.6 (4.1–20.5) 
months. Median OS for patients who underwent resec-
tion was 29.1 months compared with 7.9 months in pa-
tients who did not undergo resection (p < 0.001). 
Skeletal Muscle Mass and Density and OS
The median OS did not differ between patients with 
low and high skeletal muscle mass (10.8 [7.7–13.8] vs. 
10.3 [8.2–12.3] months, p = 0.203; Fig. 1), whereas a sig-
nificantly lower median survival was observed in patients 
with low skeletal muscle density compared with patients 
with high skeletal muscle density (7.0 [4.7–9.3] vs. 12.1 
[8.1–16.1] months, p = 0.004; Fig. 2). Kaplan-Meier sur-
vival curves for patients with high/low skeletal muscle 
mass/density stratified for treatment group (i.e., resec-
tion, laparotomy without resection, initially unresect-
able) are provided in online supplementary Figures 1–3 
(for all online suppl. material, see www.karger.com/
doi/10.1159/000486867). A sensitivity analysis using the 
cut-off defined by Martin et al. [19] showed comparable 
results (online suppl. Fig. 4, 5). 
Lower OS rates were observed in patients with low 
skeletal muscle density compared with patients with high 
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Table 1. Baseline and treatment characteristics of the total population and for patients with low and normal/high skeletal muscle mass 
and skeletal muscle density respectively
All 
(n = 233)
Skeletal muscle mass Skeletal muscle density
low (n = 103) high (n = 107) p value low (n = 131) high (n = 102) p value
Patient characteristic
Age, years, median (IQR) 66 (57–74) 69 (58–74) 64 (53–72) 0.040 72 (64–76) 59 (47–67) <0.001
Gender, n (%)
Males
Females
140 (60.1)
93 (39.9)
56 (54.4)
47 (45.6)
71 (66.4)
36 (33.6) 0.076
81 (61.8)
50 (38.2)
43 (42.2)
59 (57.8) 0.537
BMI, kg/m2* 24.7 (22.5–26.8) 23.7 (21.3–25.7) 25.7 (23.9–27.9) <0.001 25.2 (23.4–27.6) 24.4 (21.9–26.3) 0.032
ECOG (WHO) performance 
status+
1–2
3–4
215 (95.1)
11 (4.9)
94 (94.0)
6 (6.0)
99 (95.2)
5 (4.8) 0.706
118 (92.9)
9 (7.1)
97 (98.0)
2 (2.0) 0.079
Weight loss, kg, yes 118 (52.4) 50 (50.5) 60 (57.7) 0.160 68 (53.5) 50 (51.0) 0.089
Jaundice at presentation, yes 182 (80.9) 85 (85.0) 79 (76.7) 0.133 105 (82.7) 77 (78.6) 0.437
Cholangitis at/before 
presentation or preoperative 129 (56.8) 8 (8.4) 5 (4.9) 0.320 69 (54.3) 60 (60.0) 0.392
CA19-9, kU/L# 220 (57–1,297) 254 (129–1,304) 162 (41–848) 0.039 232 (67–1,351) 206 (44–877) 0.534
Albumin, g/L 38 (33–43) 38 (31–44) 39 (25–42) 0.750 37 (31–43) 38 (34–42) 0.669
Total bilirubin prior to 
drainage, µmol/L§ 138 (61–225) 146 (77–230) 120 (53–199) 0.185 155 (86–234) 122 (57–208) 0.134
C-reactive protein, mg/L¥ 13 (7–29) 19 (9–37) 9 (5–20) 0.002 17 (9–30) 9 (5–21) 0.023
Thrombocytes, ×109/L 284 (220–338) 287 (228–354) 281 (206–332) 0.266 259 (222–323) 307 (208–366) 0.174
Disease characteristic
Suspected peritoneal or other 
distant organ metastases 26 (11.2) 16 (15.5) 5 (4.7) 0.009 18 (13.7) 8 (7.9) 0.164
Lymph node status on 
imaging†
N0
N1
N2
122 (53.3)
67 (29.3)
40 (17.5)
54 (53.5)
30 (29.7)
17 (16.8)
60 (57.1)
28 (26.7)
17 (16.2) 0.858
70 (54.3)
33 (25.6)
26 (20.2)
52 (52.0)
34 (34.0)
14 (14.0) 0.267
Vascular involvement on
 imaging‡ 148 (64.9) 63 (61.2) 67 (65.0) 0.564 86 (68.3) 62 (60.8) 0.240
Tumour size on imaging, mm 22 (20–35) 25 (19–32) 27 (21–35) 0.386 26 (21–36) 26 (20–34) 0.292
Lobar atrophy on imaging 61 (26.5) 32 (31.1) 28 (26.7) 0.484 40 (31.2) 21 (20.6) 0.069
AJCC stage (radiological)
I/II
III
IV
28 (12.7)
50 (22.6)
143 (64.7)
12 (12.4)
23 (23.7)
62 (63.9)
14 (13.6)
24 (23.3)
65 (63.1) 0.968
14 (11.4)
28 (22.8)
81 (65.9)
14 (14.3)
22 (22.4)
62 (63.3) 0.810
Blumgart classification [4, 42]
Stage 1
Stage 2
Stage 3
60 (26.9)
56 (25.1)
107 (48.0)
28 (28.3)
31 (31.3)
40 (40.4)
27 (26.5)
22 (21.6)
53 (52.0) 0.190
34 (27.6)
33 (26.8)
56 (45.5)
26 (26.0)
23 (23.0)
51 (51.0) 0.697
Treatment
Treatment groups
Laparotomy with resection
Laparotomy without 
resection
No laparotomy, initially 
unresectable
41 (17.6)
72 (30.9)
120 (51.5)
18 (17.5)
29 (28.2)
56 (54.4)
23 (21.5)
43 (40.2)
41 (38.3)
0.062
17 (13.0)
24 (18.3)
90 (68.7)
24 (23.5)
48 (47.1)
30 (29.4)
<0.001
Chemotherapy 31 (14.3) 14 (14.1) 17 (17.5) 0.56 11 (8.8) 20 (21.7) 0.007
Categorical parameters are presented as counts (percentages) and continuous parameters as median (interquartile range). BMI, body mass index 
(* missing for 50 patients); ECOG, Eastern Cooperative Oncology Group (+ missing for 6 patients); CA19-9, carbohydrate antigen 19-9 (# missing 
for 77 patients); AJCC, American Joint Committee on Cancer. ¥ Missing for 92 patients. § Missing for 49 patients. † Involvement of lymph nodes was assessed according to the AJCC (7th edition) [21]. ‡ Vascular involvement on imaging was defined as tumour contact of at least 180 degrees.
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skeletal muscle density at 3 months (71.0 vs. 89.2%, p = 
0.001; OR 3.38 [1.63–7.02], p = 0.001), 6 months (51.9 vs. 
72.5%, p  = 0.003; OR 2.45 [1.11–4.26], p  = 0.002) and 
1 year (35.1 vs. 51.0%, p = 0.015; OR 1.92, [1.13–3.26], p = 
0.015), but not at 3 and 5 years (6.1 vs. 9.8%, p = 0.294, 
and 2.3 vs. 3.9%, p = 0.086, respectively). After adjusting 
for age, tumour size, and suspected peritoneal or other 
distant metastases on imaging, low skeletal muscle den-
sity was independently associated with decreased OS (HR 
1.78 [1.03–3.07], p = 0.004) ≤6 months, but not >6 months 
(HR 0.68 [0.44–1.07], p = 0.093; Table 2). Similar results 
were observed when the sex factor was added to the anal-
yses and in a subgroup analysis in unresectable patients 
only. An incremental skeletal muscle density (as a con-
tinuous measure) was also independently associated with 
decreased OS ≤6 months (HR 0.96 [0.93–0.99], p = 0.002) 
but not >6 months.
Discussion
This is the first study showing an association between 
low skeletal muscle density and worse outcome in all pa-
tients with PHC in a unique Western series of patients 
with both resectable and unresectable PHC. In other tu-
mours, such as follicular lymphoma, melanoma, and 
metastatic renal cell and gastric carcinoma, no associa-
tion between skeletal muscle mass and survival was 
shown, whereas skeletal muscle density was an indepen-
dent prognostic factor [28, 30–33]. The similarity be-
tween these studies and the current study is the aggressive 
course of the disease, which may have led to the inability 
to accurately predict outcome. 
Subgroup analyses based on treatment groups (i.e., re-
section, laparotomy without resection, initially unresect-
able), which should be interpreted with caution due to small 
sample sizes, showed non-significant differences in OS fa-
vouring patients with high skeletal muscle mass and density.
An intriguing hypothesis described by Hayashi et al. 
[32] is that a decrease in skeletal muscle density is detect-
ed earlier on CT than a decrease in skeletal muscle mass. 
Recent studies show that skeletal muscle density is main-
ly correlated with intramuscular adipose tissue content 
[27], while low skeletal muscle mass results from limited 
muscle growth and increased muscle wasting [34]. The 
mechanisms leading to and effects of these 2 processes are 
probably different and further research on their patho-
physiology is warranted. Tumour biology may play an 
important role, since the effects of skeletal muscle mass 
and density on outcome vary per tumour sort and within 
tumour sorts and altered body composition is associated 
with an elevated inflammatory response [35, 36].
The independent association between skeletal muscle 
mass and density has frequently been found in survival 
analyses of previous studies [13, 37]. Nevertheless, this is 
the first study to describe a time-dependent effect, inde-
pendently of previously described risk factors for im-
paired survival in patients with PHC [10]. Time-depen-
dency of covariates is often not assessed, leading to bias 
in survival analyses in a great part of literature [29]. Low 
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skeletal muscle density influenced OS in the 3–6 months 
after initial diagnosis. However, this effect faded hereaf-
ter. This suggests that patients with the poorest survival 
are those with the lowest skeletal muscle density and that 
skeletal muscle mass may identify patients at increased 
risk for early death. Another reason why no effect was 
found after 3 and 5 years could have been the low median 
survival time (i.e., 7.9 months in unresectable and 29.1 
months in resected patients), resulting in low patient 
numbers. Although we did not correct for treatment in 
multivariable analysis, we strongly believe that the model 
accurately reflects daily practice. After all, the parameters 
assessed at first presentation greatly determine treatment 
and consequently (indirectly) correlate with survival. Our 
results should therefore be interpreted as valid in an “all-
comers” patient population.
Notably, the rate of patients that underwent resection 
or received chemotherapy was lower in the low skeletal 
muscle density group. Furthermore, patients undergoing 
resection were significantly younger. These findings sug-
gest a preoperative selection process of patients consid-
ered fit for surgery and chemotherapy. After all, none of 
the parameters representing tumour load (i.e., bilirubin 
level, CA19-9 level, vascular involvement, tumour size) 
that possibly may have influenced resectability, were sig-
nificantly higher in patients with low skeletal muscle den-
sity. However, it should be noted that the median time 
interval between first presentation in the tertiary hospital 
and resection was 79 days. This time window may have 
led to further clinical deterioration and these findings 
should therefore be interpreted with caution. The signifi-
cantly lower BMI and higher age in patients with low skel-
Table 2. Cox proportional hazard regression analysis for factors associated with impaired survival
Univariable Multivariable
HR (95% CI) p value HR (95% CI) p value
Age, years, median (IQR) 1.02 (1.01–1.03) 0.001 1.02 (1.01–1.04) 0.003
Gender
Female
Male
1 (ref.)
1.01 (0.77–1.32) 0.945
BMI ≥25 kg/m2 1.04 (0.77–1.40) 0.803
ECOG (WHO) performance status
1–2
3–4
1 (ref.)
1.31 (0.69–2.48) 0.403
1 (ref.)
1.63 (0.72–3.69) 0.243
Bilirubin >200 µmol/L 1.48 (1.00–2.19) 0.051 1.04 (0.67–1.60) 0.866
CA19-9 >1,000 kU/L 1.87 (1.29–2.70) 0.001
Albumin, g/dL 0.99 (0.96–1.02) 0.429
C-reactive protein ≥100, mg/L 2.10 (1.05–4.18) 0.036
Cholangitis before or at presentation 1.48 (0.84–2.60) 0.180
Tumour size >3 cm 2.31 (1.72–3.09) <0.001 2.24 (1.60–3.15) <0.001
Suspicious lymph nodes on imaging*
N0
N1
N2
1 (ref.)
1.37 (1.01–1.87)
1.48 (1.03–2.13)
0.046
0.033
1 (ref.)
1.57 (1.08–2.28)
1.37 (0.91–2.06)
0.018
0.134
Suspected distant metastases on imaging 1.46 (0.97–2.20) 0.072 3.74 (1.93–7.26) <0.001
Lobar atrophy on imaging 1.04 (0.77–1.41) 0.793
Vascular involvement on imaging§ 1.44 (1.09–1.91) 0.011 1.30 (0.91–1.85) 0.150
Low skeletal muscle mass 1.99 (0.91–1.59) 0.204
Low skeletal muscle density (<6 months)# 2.09 (1.34–3.27) 0.001 1.78 (1.03–3.07) 0.040
Low skeletal muscle density (≥6 months)# 1.20 (0.85–1.69) 0.306 0.68 (0.44–1.07) 0.093
HR, hazard ratio; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; WHO, World Health Organization. * Involvement of lymph nodes was assessed according to the AJCC (7th edition) [21]. # The effect of skeletal muscle density on the hazard varied with time. Hence, an interaction term between skeletal muscle density 
and time was used to calculate the time-dependent effect of skeletal muscle density on the hazard. § Vascular involvement on imaging was defined as tumour contact of at least 180 degrees around the portal vein and/or hepatic ar-
tery and its side branches.
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etal muscle density are in line with previous findings, as 
increasing age and adiposity are known for its association 
with intramuscular adipose tissue content [19, 38].
PHC can be treated surgically or, if surgical resection 
is impossible, with non-surgical methods such as chemo-
therapy and palliative stenting. The majority of all prog-
nostic models for PHC have been developed in patients 
undergoing surgical resection [10, 21]. However, the lat-
ter group forms the greatest number of patients with 
PHC, since only around a quarter of all patients undergo 
resection [4–6]. The value of skeletal muscle mass and 
density measurements to identify patients at risk for im-
paired outcome seems promising, particularly in hepati-
copancreatobiliary cancer patients [13, 17, 18, 39]. Unfor-
tunately, the number of patients who underwent surgical 
resection was too small to validate previously described 
findings regarding CT-assessed skeletal muscle mass and 
impaired outcome in patients with PHC undergoing sur-
gery [17, 18]. Future studies should include low skeletal 
muscle density as a poor prognostic factor.
Because no uniform cut-off has been determined for 
density measurements, and optimum stratification was 
not possible due to sample size, we choose to use the sex-
specific median to group patients into low and high skel-
etal muscle density [17, 19, 23, 25, 40]. Skeletal muscle 
density and survival were entered into the survival analy-
sis as a continuous variable, since previous reports with 
large cohorts did not report sex differences in skeletal 
muscle attenuation [19]. Ideally, definitive cut-off points 
should be developed that are derived from healthy per-
sons. 
Previous studies as well as the current study show that 
sarcopenia is heavily correlated with cancer stage and 
treatment; yet across all strata of treatment and cancer 
stage, patients with sarcopenia perform worse [41, 42]. 
This indicates that, regardless of cancer stage and treat-
ment, sarcopenia is an independent predictor of out-
come. By only taking into account the preoperative sar-
copenia and radiological imaging, we believe we have de-
scribed the predictive ability of patient predisposition 
regardless of any treatment decisions. Moreover, a sub-
group analysis in non-resectable patients only showed 
similar results. This predictive information could im-
prove clinical decision-making.
Some limitations of the current study should be ac-
knowledged. A drawback is the retrospective character of 
the study design. Although a systematic search was per-
formed in the electronic patient records, this may have 
led to selection bias. Furthermore, some variables had a 
high number of missing values. In 77 patients, for exam-
ple, CA19-9 was unknown because this tumour marker 
assessment has not routinely been performed before 
2010. Although only contrast-enhanced CTs were used 
for skeletal muscle mass and density measurements, pos-
sible differences as a consequence of the use of different 
CT scanners and scanning protocols in various hospitals 
could not be precluded. Skeletal muscle mass and density 
were measured at one time only. Future studies could 
evaluate consecutive CT examinations over time to allow 
analysing changes over time.
In conclusion, a time-dependent association between 
skeletal muscle density and mortality was found in pa-
tients with PHC, regardless of subsequent treatment. Low 
skeletal muscle density may identify patients with PHC at 
risk for early death. This finding should be validated in a 
larger, external cohort, and future studies are needed to 
investigate the additional value of skeletal muscle density 
measurements in prognostic models.
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